AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1097207 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 36
Study 30421441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of cangrelor (30 μg/kg) followed by a 120‐minute infusion (4 μg/kg/min)
Number of subjects: 210
Study 30421441 — intervention group
Group type: COMPARATOR
Intervention: Matching saline placebo
Number of subjects: 210
Study 30421441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 210
Study 28285041 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants playing alone for 2 minutes
Number of subjects: 76
Study 28285041 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants playing with a caregiver for 2 minutes
Number of subjects: 76
Study 26066622 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 167
Study 26066622 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (Control)
Number of subjects: 167
Study 23125443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ENVA.01 vaccine
Number of subjects: 0
Study 21652072 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based violence prevention program (21 lessons of 75 minutes each)
Number of subjects: 1722
Study 21652072 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention schools
Number of subjects: 1722
Study 19454921 — intervention group
Group type: EXPERIMENTAL
Intervention: Media literacy program
Number of subjects: 540
Study 19454921 — intervention group
Group type: COMPARATOR
Intervention: Control (normal school lessons)
Number of subjects: 540
Study 16734961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard partner letter and website
Number of subjects: 105
Study 16734961 — intervention group
Group type: COMPARATOR
Intervention: Standard partner letter
Number of subjects: 105
Study 15229389 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus cilostazol
Number of subjects: 5
Study 15229389 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus ticlopidine
Number of subjects: 5
Study 11358941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin high dose (5.8 pmol/kg per minute)
Number of subjects: 8
Study 11358941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin low dose (2.9 pmol/kg per minute)
Number of subjects: 8
Study 11358941 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (Hemaccel)
Number of subjects: 8
Study 9433365 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of 10 mg cetirizine daily
Number of subjects: 20
Study 9433365 — intervention group
Group type: COMPARATOR
Intervention: On demand treatment with cetirizine
Number of subjects: 20
Study 8357678 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical prostaglandin E2 (PGE2) gel at a dose of 0.3 mg twice daily for 10 days
Number of subjects: 35
Study 8357678 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (placebo)
Number of subjects: 35
Study 3693870 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose of amitriptyline calculated by a pharmacokinetic test
Number of subjects: 0
Study 3693870 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of amitriptyline
Number of subjects: 0
Study 3693870 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dose of amitriptyline
Number of subjects: 0
Study 28966061 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (suture anchor technique)
Number of subjects: 29
Study 28966061 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 29
Study 27513650 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine Bicycle (SB)
Number of subjects: 12
Study 25402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural images
Number of subjects: 104
Study 25402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban with nature environments
Number of subjects: 104
Study 25402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Built‐up without nature environments
Number of subjects: 104
Study 25402210 — intervention group
Group type: EXPERIMENTAL
Intervention: Built‐up without nature environments with striking architectural qualities
Number of subjects: 104
Study 23368420 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived control of asthma
Number of subjects: 175
Study 23368420 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased anxiety
Number of subjects: 175
Study 19545929 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m² on day 1 and pemetrexed 500 mg/m² followed by gemcitabine 1250 mg/m² on day 8 of a 3-week cycle (GA arm)
Number of subjects: 105
Study 19545929 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 120 mg/m² followed by gemcitabine 1000 mg/m² on days 1 and 8 of a 3-week cycle (PG arm)
Number of subjects: 105
Study 18974515 — intervention group
Group type: EXPERIMENTAL
Intervention: Two hours occlusion therapy
Number of subjects: 100
Study 18974515 — intervention group
Group type: EXPERIMENTAL
Intervention: Four hours occlusion therapy
Number of subjects: 100
Study 18974515 — intervention group
Group type: EXPERIMENTAL
Intervention: Six hours occlusion therapy
Number of subjects: 100
Study 18974515 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time occlusion therapy
Number of subjects: 100
Study 18974515 — intervention group
Group type: COMPARATOR
Intervention: Mild to moderate amblyopia (vision 20/30 to 20/80)
Number of subjects: 100
Study 16828460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day behavioral group treatment (BGT) program
Number of subjects: 150
Study 16828460 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day cognitive-behavioral group treatment (CBGT) program
Number of subjects: 150
Study 16828460 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL) control group
Number of subjects: 150
Study 12798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintile of serum hematocrit (Hct) (range 25.4% to 37.5%)
Number of subjects: 1130
Study 12798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1% decrease in Hct within the lowest quintile
Number of subjects: 1130
Study 12798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quintiles of Hct (not specified)
Number of subjects: 1130
Study 12798560 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower Hct
Number of subjects: 1130
Study 11139926 — intervention group
Group type: EXPERIMENTAL
Intervention: BS45D lead model
Number of subjects: 30
Study 11139926 — intervention group
Group type: COMPARATOR
Intervention: S84F lead model
Number of subjects: 30
Study 11139926 — intervention group
Group type: COMPARATOR
Intervention: S44F lead model
Number of subjects: 30
Study 8970857 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory information (procedural, sensory, and coping information) with written support
Number of subjects: 82
Study 8970857 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine advice and support from ward, medical and nursing staff)
Number of subjects: 82
Study 8970857 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory information (various types and forms)
Number of subjects: 82
Study 1360452 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination FSH/hMG
Number of subjects: 5
Study 1360452 — intervention group
Group type: COMPARATOR
Intervention: hMG only
Number of subjects: 5
Study 2936353 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 130
Study 2936353 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 130
Study 2936353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 29666901 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dexmedetomidine (1 μg/kg)
Number of subjects: 10
Study 29666901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (1 μg/kg)
Number of subjects: 10
Study 27223147 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived factor VIII
Number of subjects: 264
Study 27223147 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant factor VIII
Number of subjects: 264
Study 25531119 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 mEq/l dialysate calcium
Number of subjects: 56
Study 25531119 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mEq/l dialysate calcium
Number of subjects: 56
Study 22032797 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 0
Study 22032797 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 0
Study 22032797 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio
Number of subjects: 0
Study 20308817 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/remifentanil (group S)
Number of subjects: 302
Study 20308817 — intervention group
Group type: COMPARATOR
Intervention: Propofol/remifentanil (group P)
Number of subjects: 302
Study 18280787 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Problem List (APL) system
Number of subjects: 247
Study 18280787 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard problem list management)
Number of subjects: 247
Study 15772402 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour educational intervention (N=18)
Number of subjects: 32
Study 15772402 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=14)
Number of subjects: 32
Study 12725416 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2 mg/dienogest 2 mg (E2V/DNG)
Number of subjects: 45
Study 12725416 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 45
Study 12725416 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (E2V/DNG and E2/NETA)
Number of subjects: 45
Study 10572887 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral diode laser coagulation
Number of subjects: 30
Study 10572887 — intervention group
Group type: COMPARATOR
Intervention: Transpapillary diode laser photocoagulation
Number of subjects: 30
Study 8609551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 1202
Study 8609551 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1202
Study 1655056 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g in a single dose
Number of subjects: 62
Study 1655056 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg in a single dose on day 1 followed by 250 mg once daily for 2 days
Number of subjects: 62
Study 1655056 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 200 mg in a loading dose followed by 100 mg every 12 h for 7 days
Number of subjects: 62
Study 6820887 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (more than 60 g)
Number of subjects: 1673
Study 6820887 — intervention group
Group type: EXPERIMENTAL
Intervention: Method II (large dose MMC) plus Futraful
Number of subjects: 1673
Study 6820887 — intervention group
Group type: COMPARATOR
Intervention: Group A (without Futraful)
Number of subjects: 1673
Study 29532291 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg kg-1
Number of subjects: 30
Study 29532291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) 6 mg kg-1 of maltodextrin
Number of subjects: 30
Study 28130432 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (2 g)
Number of subjects: 829
Study 25811544 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine (0.3 g·kg‐1·day‐1 + 0.3 g·kg‐1·day‐1 maltodextrin)
Number of subjects: 16
Study 25811544 — intervention group
Group type: EXPERIMENTAL
Intervention: L-glutamine
Number of subjects: 16
Study 25811544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin, 0.6 g·kg‐1·day‐1)
Number of subjects: 16
Study 24092942 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering regimens (various drug classes including ACE inhibitors, calcium antagonists, diuretics/β blockers)
Number of subjects: 152290
Study 24092942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152290
Study 22146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine
Number of subjects: 144
Study 22146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakonein
Number of subjects: 144
Study 22146628 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax Notoginsenoside
Number of subjects: 144
Study 22146628 — intervention group
Group type: COMPARATOR
Intervention: Model Control
Number of subjects: 144
Study 22146628 — intervention group
Group type: EXPERIMENTAL
Intervention: All Treated Groups
Number of subjects: 144
Study 19153290 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosseal (2 mL sprayed under the skin flap)
Number of subjects: 9
Study 19153290 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 9
Study 19153290 — intervention group
Group type: EXPERIMENTAL
Intervention: Crosseal (treated side)
Number of subjects: 9
Study 17362570 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling HPV test
Number of subjects: 920
Study 17362570 — intervention group
Group type: COMPARATOR
Intervention: Clinician HPV test
Number of subjects: 920
Study 17362570 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 920
Study 15302637 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/d for 10 days
Number of subjects: 121
Study 15302637 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 121
Study 15532006 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise protocol
Number of subjects: 14
Study 15532006 — intervention group
Group type: EXPERIMENTAL
Intervention: Rampwise protocol
Number of subjects: 14
Study 10193720 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine at 20 mg once a day
Number of subjects: 68
Study 10193720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10193720 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 68
Study 8520811 — intervention group
Group type: EXPERIMENTAL
Intervention: MID 10 mg + 150 mg fluconazole (FLU)
Number of subjects: 5
Study 8520811 — intervention group
Group type: COMPARATOR
Intervention: MID 10 mg
Number of subjects: 5
Study 8520811 — intervention group
Group type: EXPERIMENTAL
Intervention: MID 10 mg after FLU
Number of subjects: 5
Study 8520811 — intervention group
Group type: EXPERIMENTAL
Intervention: MID 10 mg after 750 mg erythromycin (ERY)
Number of subjects: 5
Study 8520811 — intervention group
Group type: COMPARATOR
Intervention: MID 10 mg alone
Number of subjects: 5
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 150 mg
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 300 mg
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 500 mg
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg (30 min after breakfast)
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole 200 mg t.i.d. (20 min before meals for 7 days)
Number of subjects: 0
Study 2271746 — intervention group
Group type: EXPERIMENTAL
Intervention: Midaglizole (all doses)
Number of subjects: 0
Study 7416592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 mg of naloxone
Number of subjects: 6
Study 7416592 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion of normal saline
Number of subjects: 6
Study 31831920 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin 2%
Number of subjects: 96
Study 31831920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin 2% and Sucralfate 7% combination
Number of subjects: 96
Study 31831920 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: Midcooling (facial water spray and menthol mouth rinse)
Number of subjects: 11
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: All methods combined (PRE, MID, ALL)
Number of subjects: 11
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: Precooling (cold-water immersion and ice slurry ingestion)
Number of subjects: 11
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: All conditions (PRE, MID, ALL)
Number of subjects: 11
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: Midcooling
Number of subjects: 11
Study 27379961 — intervention group
Group type: COMPARATOR
Intervention: Precooling
Number of subjects: 11
Study 25697494 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3060
Study 25697494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Number of subjects: 3060
Study 25697494 — intervention group
Group type: COMPARATOR
Intervention: Control (lowest risk quarter)
Number of subjects: 3060
Study 25050898 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (INT)
Number of subjects: 30
Study 25050898 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 30
Study 25050898 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (REF)
Number of subjects: 30
Study 22520674 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for estimating absolute risk of pancreatic cancer
Number of subjects: 375
Study 19265095 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent direct current cardioversion
Number of subjects: 0
Study 19265095 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I antiarrhythmic drugs (flecainide, propafenone)
Number of subjects: 0
Study 19265095 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III antiarrhythmic drug (amiodarone)
Number of subjects: 0
Study 19265095 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers and rate limiting calcium blockers, digoxin
Number of subjects: 0
Study 17376187 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglactin sutures
Number of subjects: 32
Study 17376187 — intervention group
Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 32
Study 15383112 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radio-frequency ablation (NovaSure)
Number of subjects: 126
Study 15383112 — intervention group
Group type: COMPARATOR
Intervention: Balloon ablation (ThermaChoice)
Number of subjects: 126
Study 11522497 — intervention group
Group type: EXPERIMENTAL
Intervention: epalrestat (150 mg/day) for 5 years
Number of subjects: 35
Study 11522497 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 9640123 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion of Propofol
Number of subjects: 562
Study 9640123 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion of Propofol
Number of subjects: 562
Study 7973776 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (Ethyol)
Number of subjects: 0
Study 30321960 — intervention group
Group type: EXPERIMENTAL
Intervention: Weil osteotomy (WO)
Number of subjects: 60
Study 30321960 — intervention group
Group type: COMPARATOR
Intervention: Distal metatarsal metaphyseal osteotomy (DMMO)
Number of subjects: 60
Study 28454526 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free 0.0015% tafluprost (NPT)
Number of subjects: 20
Study 28454526 — intervention group
Group type: COMPARATOR
Intervention: Preservative containing 0.0015% tafluprost (PT)
Number of subjects: 20
Study 26188896 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of procaine 0.5% at 4-5 ml/h for 48 hours via elastomeric pump
Number of subjects: 109
Study 26188896 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative pain regimen of metamizole 1 g and/or ketorolac 3% - 30 mg
Number of subjects: 109
Study 24622000 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge heart rate ≥70 beats/min
Number of subjects: 1947
Study 20652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 955
Study 20652857 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopy
Number of subjects: 955
Study 20652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniprobe EUS
Number of subjects: 955
Study 20652857 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial EUS
Number of subjects: 955
Study 17237328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined iron (10 mg) and zinc (10 mg) supplementation for 6 months
Number of subjects: 2468
Study 17237328 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (10 mg) supplementation for 6 months
Number of subjects: 2468
Study 17237328 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10 mg) supplementation for 6 months
Number of subjects: 2468
Study 17237328 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A capsules (VAC) administration
Number of subjects: 2468
Study 15689350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (UG-ET)
Number of subjects: 67
Study 11975390 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10436401 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy (PTX) without autotransplantation in hemodialysis patients (group I)
Number of subjects: 16
Study 10436401 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parathyroidectomy (PTX) without autotransplantation in patients without renal insufficiency (group II)
Number of subjects: 16
Study 7786974 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy combined with anti-depressive medication
Number of subjects: 31
Study 7786974 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only anti-depressive medication
Number of subjects: 31
Study 1972349 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol 200 mg twice daily for 3 months
Number of subjects: 30
Study 1972349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 119258 — intervention group
Group type: EXPERIMENTAL
Intervention: +amphetamine (10 mg)
Number of subjects: 0
Study 119258 — intervention group
Group type: EXPERIMENTAL
Intervention: +/-fenfluramine (30 mg and 60 mg)
Number of subjects: 0
Study 119258 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 31888711 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 187